Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: a Systematic Review

Abstract

Conventional treatments for brain tumors relying on surgery, radiation, and systemic chemotherapy are often associated with high recurrence and poor prognosis. In recent decades, intra-arterial administration of anti-cancer drugs has been considered a suitable alternative drug delivery route to intravenous and oral administration. Intra-arterial administration is believed to offer increasing drug responses by primary and metastatic brain tumors, and to be associated with better median overall survival. By directly injecting therapeutic agents into carotid or vertebral artery, intra-arterial administration rapidly increases intra-tumoral drug concentration but lowers systemic exposure. However, unexpected vascular or neural toxicity has questioned the therapeutic safety of intra-arterial drug administration and limits its widespread clinical application. Therefore, improving targeting and accuracy of intra-arterial administration has become a major research focus. This systematic review categorizes strategies for optimizing intra-arterial administration into five categories: (1) transient blood-brain barrier (BBB)/blood-tumor barrier (BTB) disruption, (2) regional cerebral hypoperfusion for peritumoral hemodynamic changes, (3) superselective endovascular intervention, (4) high-resolution imaging techniques, and (5) others such as cell and gene therapy. We summarize and discuss both preclinical and clinical research, focusing on advantages and disadvantages of different treatment strategies for a variety of cerebral tumor types.

Introduction

Brain tumors are a large class of heterogeneous neoplasms, generally classified as benign or malignant tumors. It is widely believed that uncontrolled proliferation and tissue infiltration of dedifferentiated cells caused by harmful chemical, physical, and biological exposures are the main causes of brain tumor malignancy (1). Non-malignant brain tumors also can pose a much higher risk than elsewhere in the body, in particular when situated in areas hard to reach by surgical interventions. According to the latest statistics from the United States Central Brain Tumor Registry, the average annual incidence of brain and other central nervous system (CNS) tumors (malignant and non-malignant) after age adjustment was 23.03 per 100,000 people (2). Moreover, a worldwide meta-analysis reported that the total incidence of primary brain tumors was 10.82 per 100,000 person-years, with an estimated range of 0.01 (pineal tumors) to 25.95 (all primary brain tumors) per 100,000 people (1). As of 2011, several population-based studies indicated that the incidence of metastatic brain tumors was 7–14 per 100,000 people (3), thus accounting for 2% of all cancers and 12.1% of metastatic diseases (4). The brain tumor incidence is related to a variety of factors, such as the type, location, and grade of a primary tumor in case of metastases, as well as the age, gender, ethnicity, and risk factor exposure of the patients (1, 5). For example, primary brain tumors are most common in children aged 0–14 years (2, 6) and include hair cell astrocytoma, embryonic tumors, and malignant gliomas (6). Meningiomas have the highest incidence of all adult primary brain tumors (3), followed by malignant gliomas and pituitary tumors (3, 4). It is noteworthy that brain metastases are more common in adults, with lung cancer, breast cancer, and melanoma showing the highest rates (3, 4).

Brain tumors are relatively rare compared to other neurological diseases, and complex pathogenesis of some brain tumor types (especially malignant gliomas) often renders existing treatment strategies ineffective in prolonging survival time. Thus, brain tumors are the most life-threatening cancers in humans (7). The traditional treatment of brain tumors is the combination of surgery, radio- and chemotherapy (8). Surgery targets at the removal of tumor tissue. Radio- and chemotherapy as primary or adjuvant treatments have a positive effect on improving the survival rate of selected patients (9) and can reduce tumor mass prior to surgery. Anti-tumor effects are not only based on drug dose and tumor sensitivity but also related to the route of drug delivery. In general, drug binding to plasma proteins or lipids in the peripheral circulation and the target organ metabolism affect therapeutic effects after systemic administration (10). Systemic exposure in non-targeted organs caused by intravenous and oral administration are also an important factor restricting long-term use of chemotherapy drugs (11).

Intra-arterial administration was first described for the treatment of brain tumors in the 1950s (12). In comparison to intravenous delivery, intra-arterial administration increases intra-tumor drug concentration and accelerates systemic clearance (13). Up to now, intra-arterial administration has been shown to exert positive effects on recurrent or progressive malignant glioblastomas (14), retinoblastomas (15), and primary CNS lymphomas (16). However, severe vascular toxicity and neurotoxicity have been reported in several clinical studies. For example, patients with primary glioblastomas or anaplastic astrocytomas receiving intra-arterial cisplatin often experience significant loss in high-frequency hearing (17, 18). Moreover, patients with newly diagnosed or recurrent malignant gliomas or other brain tumors suffer from decreased visual acuity and irreversible encephalopathy (e.g., cerebral edema and leukoencephalopathy) when receiving intra-arterial carmustine 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) (19, 20). Myelosuppression mostly occurs in patients with primary CNS lymphomas who have received intra-arterial nitrosourea 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) and radiotherapy (21). Myelosuppression is also the most common side effect of intra-arterial cisplatin combined with oral etoposide in the treatment of recurrent malignant gliomas (22). Other relatively common complications include nausea, vomiting, thrombocytopenia, seizures, ocular pain, headache, intratumoral hemorrhage, transient cerebral ischemia, granulocytopenia, nephrotoxicity, and vasospasm (19, 21, 23–27). Radiotherapy before intra-arterial administration may contribute to white matter necrosis (20, 28). Moreover, technical (e.g., perfusion strategy and artery selection) and pharmacological factors (e.g., drug dosage and compatibility) can affect safety, accuracy, and efficacy of intra-arterial administration (29–31) and have not been discussed in detail so far.

On the other hand, a number of strategies to improve the therapeutic effects of intra-arterial administration for the treatment of brain tumors have been suggested. This systematic review summarizes the five most important ones. The first option is blood–brain barrier (BBB)/blood-tumor barrier (BTB) disruption using chemical reagents (such as mannitol, bradykinin, or alkylglycerols) or penetration drug carriers (such as liposomes, micelles, cell-penetrating peptides) to increase the direct entry of drugs into tumor and brain tissues. The second option is intra-arterial injection during transient cerebral hypoperfusion (IA-TCH) or flow arrest (IA-FA). This increases local plasma drug concentration and exposure time by reducing dilution, absorption, and contact with blood components. The third option are microcatheters designed to allow superselective intra-arterial cerebral infusion (SIACI) into the tumor-feeding arteries to reduce neurotoxic side effects while achieving well-targeted drug delivery. The fourth option is to combine imaging techniques, such as MRI, CT, X-ray, SPECT, and PET with intra-arterial infusion of labeled therapeutic agents, to monitor delivery and accumulation in the tumor and brain parenchyma. The fifth option is to use advanced techniques including intra-arterial infusion of gene-edited viruses or cells to achieve targeted molecular or cell therapy for brain tumors. Next to providing an overview, this review also discusses advantages and limitations of these different strategies that became obvious in preclinical and clinical research.

Methodological Approach

Literature search and evaluation were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) standard. No ex-ante protocol was used.

A systematic literature search was conducted in three databases: EMBASE, PubMed, and Web of Science. The original search date was October 22, 2019 (n = 1,835) and updated on June 30, 2020 (n = 1,855). One more study was included during the updated search. The publication time in EMBASE was 1963–2020, PubMed 1962–2020, and Web of Science 1946–2020. A keyword-based search strategy was applied as follows: In EMBASE, the keyword terms “brain tumor” and “intraarterial drug administration” of EMTREE dictionary were used. The MeSH-defined keywords “Brain Neoplasms” and “Injections, Intra-Arterial” or “Infusions, Intra-Arterial” were used in PubMed searches, while Web of Science searches were conducted with “Brain tumor” and “Intra arterial.” In addition, other eligible publications selected from the list of references in the included literature were used to supplement the search results. Only peer-reviewed articles published in English were included. The included literature should focus on strategies that aimed at improving the therapeutic effect of intra-arterial treatment. Therefore, articles that simply evaluated the therapeutic effects of intra-arterial administration but without comparing them to alternate approaches were excluded (n = 105). We also excluded conference abstracts (n = 10), papers without available full-text (n = 3), papers not reporting brain tumor treatment (n = 21), and in-vitro studies (n = 5), as well as studies not reporting intra-arterial treatment (n = 4) or being focused on embolization only (n = 5). Reviews were also excluded (n = 28).

Results

Data Set

A total of 1,855 articles were retrieved from EMBASE (n = 486), PubMed (n = 534), and Web of Science databases (n = 835). By screening the reference lists of the included papers, one more publication was added to the search results, resulting in a total of 1,856 articles. Screening for duplicates and their removal resulted in a total of 1,070 articles. We next screened titles and abstracts, obtaining 399 articles not meeting any exclusion criterion. Finally, 218 articles published between 1981 and 2020 were included after full-text evaluation (Figure 1A), what allowed us analyzing literature output in the previous four decades.

Figure 1

We then grouped articles according to the strategies described for optimizing intra-arterial administration of therapeutic agents to brain tumors. There were 94 studies focusing on BBB/BTB disruption, 24 on TCH, 39 on SIACI, 33 on imaging-guided approaches, and 46 on other therapeutic agents and methods (Figure 1B).

As shown in Figure 1C, research on optimization strategies changes with the development of new technologies. The majority of studies focused on BBB disruption and were most frequently published 1991–2000 (n = 42). Numbers of studies focusing on BBB disruption gradually decreased from 2001. However, the number of publications on BBB disruption was still higher (2001–2010) than or equal to (2011–2020) the numbers of studies focusing on other strategies. Research on nanoparticles became a main research focus for improving BBB/BTB penetration in the past decade (2011–2020). Several techniques emerging from medical physics were applied in preclinical research on TCH (n = 10). With the improvement of microcatheters, superselective infusion techniques gradually became a routine treatment option in 2011–2020 (n = 14). In parallel, real-time image-based monitoring became increasingly important for optimization of therapeutic procedures (n = 14).

Strategies for Improved Intra-Arterial Drug Delivery to Brain Tumors

BBB/BTB Disruption

The BBB represents a major obstacle for CNS drug delivery (32). The anatomy of BBB, mainly composed of brain endothelial cells, astrocytes, and pericytes (33), has been well studied. The tight junctions of endothelial cells are the mainstay of the barrier structure (34), while transcellular carriers and cell surface receptors (35) allow the selective transport of nutrients and metabolites (36) across the BBB. Morphology and function of BBB often change under pathological conditions (37). It has been found that the BBB is damaged in primary tumors such as meningiomas (38), schwannomas (39), and high-grade gliomas (40), but this does not necessarily facilitate drug uptake (41). On the other hand, excessive BBB permeability increases the risk of cerebral edema (42). Therefore, reasonable and targeted changes in BBB permeability are critical to increase drug uptake while at the same time minimizing drug dose and adverse effects.

Some chemical agents have been shown to modify the BBB (Table 1). The hypertonic solution mannitol (80) draws water from endothelial cells into blood vessels, causing endothelial cell shrink. This impacts tight junctions, allowing drugs to pass the BBB (81, 82). Reagents with comparable effects comprise arabinose (83) and hypertonic urea (84). To date, mannitol remains one of the most effective hyperosmotic solutions for transient BBB disruption. Mannitol is safe and well-tolerated in combination with intra-arterial chemotherapy (Table 2). The approach increases BBB permeability and thus facilitates the use of relatively large-sized antibodies (e.g., bevacizumab and cetuximab) for the treatment of malignant glioma (100, 101, 107). It improves therapeutic effects of methotrexate and carboplatin on primary CNS lymphomas and cerebral metastases (93, 98). The risk for cognitive impairment was reduced when mannitol-mediated BBB disruption was used together with radiotherapy in patients with germ cell tumors (113). A multi-center study also confirmed the benefits of intra-arterial chemotherapy with osmotic BBB disruption in enhancing the therapeutic response of primitive neuroectodermal tumors (94). By detecting ^99mTc-glucoheptonate (TcGH), SPECT scans confirmed BBB opening within 40 min after mannitol injection and returned to the steady state after 6–8 h. This provides a wide time window for clinical applications (82). However, preclinical studies revealed that BBB disruption with mannitol is variable (114) and may cause an unexpected increase in transcapillary transport of anticancer drugs into healthy brain tissues (45, 115). In both humans and experimental animals (e.g., pigs and rats), focal motor seizures occur during BBB opening and last for several hours after termination of the procedure. The presence of high-frequency and high-amplitude electroencephalography (EEG) signals suggests that intra-arterial injection of mannitol through the anterior circulation may directly affect the motor cortex, regardless of the size and location of the tumor, or applied chemotherapy (116, 117). Other potential complications such as tachycardia and increased intracranial pressure as well as nausea, headache, and vomiting have been reported retrospectively (118). BBB disruption may also result in transient aphasia, hemiparesis, or even edema-induced intracranial herniation (94). Some conditions can affect mannitol-mediated BBB opening (114). For example, low brain temperature and the Na⁺/Ca²⁺ exchange blocker KB-R7943 enhance mannitol-mediated BBB opening (119), while intraperitoneal administration of magnesium sulfate attenuates mannitol effects (120). Thus, hyperosmotic mannitol infusion remains challenging and is hard to control, even though most side effects seem mild and can be controlled by medications (98, 102).

The BTB is found on tumor capillaries and can have a continuous non-fenestrated, continuous fenestrated or discontinuous phenotype (121). The surface receptor profile of BTB capillaries is more heterogeneous than that of normal capillaries (41, 122). Intra-arterial infusion of bradykinin (57), its analog RMP-7 (known as Cereport^® or Lobradimil, a widely used adjuvant chemotherapy reagent) (59), 1-O-pentylglycerol (66), or calcium antagonists (71) into rats transplanted with different tumor cell lines significantly increases BTB permeability. However, blood volumes within the tumor or the surrounding brain remain unchanged (Table 1). RMP-7 penetrates the BTB by activating B2 receptors on endothelial cells (60), which seems to be regulated by the NO-cyclic GMP pathway (123, 124). Infusion of RMP-7 also enhances intra-arterial delivery of a therapeutic herpes simplex virus vector (64, 125) and tumor uptake of carboplatin (61, 126). Short-chain alkylglycerols promote delivery of methotrexate (68) (Table 2). In Fischer 344 rats with gliosarcoma, bradykinin fosters selective herpes simplex virus infection in multiple tumor foci and increases the absorption of single crystal iron oxide nanoparticles (127). Moreover, histamine has a selective effect on increasing BTB permeability that is mediated by H2 receptors (70). Animal experiments demonstrated that intra-carotid infusion of leukotriene C4 (75) and E4 (76) increase BTB permeability, but do not affect normal brain capillaries. Preclinical evaluation of RMP-7 indicated a high efficacy in tumor uptake but minimal disturbance to normal tissues. It can, however, cause rapidly emerging side effects including hypotension, hypertension, abdominal pain, vasodilatation, headache, nausea, tachycardia, fatigue, and vomiting during intravenous infusion in a dose-dependent manner (128). RMP-7 may also cause leukopenia, nausea, thrush, cellulitis, urinary tract infection, hematuria, weakness, seizures, sensory loss, cortical blindness, oculomotor nerve palsy, and even ischemic stroke at the maximum intra-arterial infusion dose of 300 ng/kg (110, 112). However, the RMP-7-induced BBB/BTB permeability is transient and the barrier can spontaneously recover even during RMP-7 administration. This makes it difficult to define the optimal dosing and timing paradigm of RMP-7 in order to promote the maximum intratumoral concentration of chemotherapeutic agents (129, 130). Therefore, any potential beneficial effects from RMP-7-mediated drug delivery need to be confirmed in further clinical investigations.

Importantly, drugs used for tumor treatment may also exert effects on the BBB (Table 1). Intra-carotid infusion of vinorelbine into rats increases local BBB permeability at high doses (74), although recent data show much lower vinorelbine efficacy in brain vs. peripheral metastases (131). Cisplatin (73) and etoposide (72) were reported to open the BBB, and this effect precedes changes in local cerebral blood flow and necrosis. BBB opening may therefore be a sensitive indicator of cisplatin and etoposide neurotoxicity during intra-arterial administration (73). However, cisplatin is known for its acute gastrointestinal toxicity causing nausea and vomiting and can lead to myelosuppression (132). Etoposide has systemic side effects, including leukopenia, thrombocytopenia, and anemia when used with carboplatin (133). Another main obstacle that restricts further application of cisplatin and etoposide is their unknown mechanism. Whether the capability of these drugs to bypass the BBB is due to increased bradykinin release or P-glycoprotein expression in newly formed vessels (134) remains uncertain and requires future research.

Recently, it has been found that convection-enhanced delivery (CED) using catheters stereotactically inserted into brain tumors fosters drug delivery into these tumors and surrounding brain tissue by establishing a local positive pressure gradient (135). In contrast to diffusion-based concentration gradients, CED has advantages when applying compounds of high molecular weight because of a BBB bypass (135, 136). A main application of CED is the targeted delivery of cytotoxin to the tumor parenchyma or the surrounding tissues with encouraging results being reported for glioblastoma multiforme (137, 138). However, there is not yet convincing evidence for a benefit of CED in other chemotherapeutic paradigms even though preliminary experience is promising. In a F98 glioma rat model, CED of platinum-based drugs and liposomes increases drug accumulation in tumor tissue and extends the median survival time (139). CED of carboplatin has also been reported to have a sound therapeutic effect on glioblastomas in a Phase I clinical trial (140). However, there are a number of side effects caused by CED, such as headache, seizure, fever, nausea, vomiting, fatigue, erythema, and even liver enzyme perturbations and hematological changes (141, 142), which are related to the time and location of the treatment (143). Factors such as catheter reflux, leakage, or improper imaging guidance may lead to treatment failure (144).

Focused ultrasound is a novel non-invasive strategy for reversibly disrupting BBB tight junctions. Application of low frequency continuous wave ultrasound (~10 ms bursts, 1 MPa amplitude, 1 Hz frequency for 20–30 s intervals) generated well-controllable damage to tumor tissue, but minimal disturbance to surrounding healthy brain tissue (145). Microbubbles are standard ultrasound contrast agents and can help to create large shear microstreaming to open the capillary wall (146). Doxorubicin encapsulated in liposomes significantly accumulates in the rat brain after MRI-guided focused ultrasound with microbubbles (147) and has been investigated in a patient with high-grade glioma recently (148). Using the same strategy, focused ultrasound enhances the delivery of BCNU by intravenous administration to normal and C6 glioma-implanted rat brain tissue (149) as well as methotrexate to the rabbit brain (150). The most severe side effects are necrosis, febrile seizures, hemorrhage, and brain edema. Other complications include tolerable back pain and self-limiting headache (151, 152). Focused ultrasound may offer a promising method greatly improving local drug delivery after intra-arterial administration, but more evidence for clinical safety, efficacy, and feasibility is required.

The recent advent of nanotechnology has led to widespread nanoparticle applications in intra-arterial administration (Table 3). Due to the ability to pass through the BBB, some nanoparticles can be used for intra-arterial drug delivery (168). The cationic (positive) charge on their surface increases homing toward negatively charged tumor cell surfaces (169). It has been demonstrated that intra-arterial injection of paclitaxel-loaded cationic, polymeric, and magnetic liposomes increases drug delivery to the tumor tissue (156). When combined with BBB disruption induced by focused ultrasound, intra-arterial liposome injection increases their deposition into tumor tissue of C6 tumor-bearing rats (158). Similarly, application of cationizable lipid micelles (163) with cationic short peptides such as the cell-penetrating trans-activator of transcription (TAT) was shown to increase the uptake of micelles (165) and can be used for selective drug delivery to gliomas. The translocation efficiency of nanoparticles is not only determined by surface charge. For instance, larger particles are more likely to adhere to the vessel wall, but the hydrodynamic resistance for BBB crossing is also increased (162). Other parameters such as shape, lipophilicity, and ligand density can affect effective BBB penetration of nanoparticles (170). More research is needed to optimize intra-arterial nanoparticles delivery protocols for future applications.

TCH

The pharmacokinetic theory of intra-arterial drug administration suggests that a comparable tumor response can be obtained faster by intra-arterial than by intravenous administration due to the first pass effect. Regional slow blood flow can increase tissue drug levels and rapid systemic clearance (171). In a non-human primate model, phased pulsatile infusion during the diastole resulted in excellent distribution of the drug in blood (172). Intra-arterial drug administration during cerebral hypoperfusion promotes drug deposition in tumor and surrounding tissues, increases the contact time of drugs with tumor cells, and avoids non-targeted binding to plasma proteins (173). Hence, such improved methods increase drug concentrations in the tumor tissue while at the same time enabling reduction of the overall amount of drugs infused, mitigating potential side effects (174, 175).

Almost 30 years ago, it was shown that glucose reduces the pH of tumors by reducing blood flow, which in turn promotes thermochemotherapeutic effects (176). Various vasodilators such as adenosine (177), histamine (178), or iloprost (179) have been considered to alter regional cerebral blood flow in brain and tumor capillaries. Adenosine was shown to promote endovascular embolization during arteriovenous malformation by transient induction of hypotension (180). Taking advantage of this, a decrease in mean arterial blood pressure can be achieved by intravenous injection of adenosine, esmolol, and large doses of cold saline. When combined with bilateral carotid occlusion, cerebral blood flow measured by a laser Doppler probe would transiently drop to 10–20% for 30–40 s and completely recover within 5 min without inotropic support. This procedure allows intra-arterial injection of less mannitol to achieve BBB disruption lasting at least 60 min (174). It has been shown that TCH can improve the uptake of lipophilic drugs (e.g., BCNU) into rabbit brains without causing severe neuronal damage or abnormal EEG signals (181). In glioma-bearing rats, it was found that a combination of lowering cerebral blood flow and BBB opening increases the concentration of the chemotherapeutic drug (e.g., mitoxantrone) in glioma tissue more than 10-fold as compared to the contralateral, tumor-free brain tissue. The treatment effect was reported to last for more than 4 h (175). Furthermore, TCH is sufficient to enhance early regional deposition of nanoparticles such as micelles (163–165) and liposomes (158–162) into tumor tissues. This provides a novel approach for targeted intra-arterial tumor therapy (Table 3).

Despite these promising findings, the translation of TCH-promoted intra-arterial drug administration to brain tumors into clinically applicable procedures is still not completed. Although the strategy has been validated in standardized animal models, tumor response and survival time after intra-arterial drug administration in humans were not yet described. TCH has been widely used in neurosurgical procedures for the treatment of arteriovenous malformations and aneurysms, but drug distribution in tumor vessels is complex and blood flow might be variable. Moreover, a relatively high risk of systemic hypotension or regional low cerebral blood flow is a challenge for the clinical application of TCH in intra-arterial drug administration.

SIACI

In theory, primary brain tumors usually have a limited number of supplying arteries. This is advantageous when considering treatment by superselective intra-arterial infusion (182). However, since the ophthalmic artery originates from the internal carotid artery, drugs injected into the internal carotid artery also reach the eye, which can injure retinal ganglion cells and lead to temporary or permanent ocular complications (183) such as vision loss, vasculitis, and cataracts (184). Hence, it is reasonable to selectively inject into the main tumor-supplying arteries rather than infusing into major brain supplying vessels, such as the carotid or vertebral arteries (185). In clinical practice, the tip of a superselective catheter is usually placed in the A1 segment of the anterior cerebral artery, the M1 segment of the middle cerebral artery, or in the posterior communicating artery (182). Supraophthalmic carotid infusion became the preferred procedure to prevent drugs from entering the eye (184, 186–191). Flow-directed soft-tipped balloon or single-lumen catheters (188) with an extended tip (182–184) can be remotely controlled by hydraulic forces (189) and allow to maneuver even in extremely curved skull base vessels (184). It has been reported that supraophthalmic carotid chemotherapy can be used to treat malignant gliomas with low dose cisplatin and BCNU (182, 191, 192), and that the pharmacokinetic changes of ¹¹C-BCNU are consistent with the metabolic changes captured by PET (185). In combination with external beam radiation therapy, supraophthalmic infusion of fluorouracil was reported to achieve acceptable median survival rates in anaplastic astrocytomas and glioblastomas (193). Superselective intra-arterial infusion of bevacizumab (100, 103) or cetuximab (107, 108) combined with mannitol-mediated BBB opening exerts profound anti-proliferative effects (194) and reduces tumor volume. The procedure was proven to be safe and effective in the treatment of brainstem gliomas (104) and multiply recurrent pediatric ependymoma (106) as well as vestibular schwannomas (195). However, it is still unclear whether long-term slow infusion or rapid bolus infusion is the more effective approach (182). It was recently shown that median progression-free survival of patients with recurrent glioblastoma receiving a single dose of SIACI 15 mg/kg bevacizumab and mannitol is comparable or even longer than that of those who received biweekly intravenous bevacizumab at 10 mg/kg (102). Moreover, side effects including epilepsy and headache indicate a need for careful dose adjustments in therapies relying on multiple administrations (102). Adverse events during invasive procedures further include nausea, bradycardia, vomiting, headache, and vascular complications such as asymptomatic subintimal tear, and even intracranial herniation, stroke, and cerebral hemorrhage. Thus, extensive experience in endovascular intervention is required to apply superselective intra-arterial drug administration (94, 133). Favorable results have been reported for a patient suffering from metastatic breast cancer. Skull and dura mater metastasis disappeared after repeatedly performed superselective intra-arterial administration of epirubicin into the right superficial temporal artery and the middle meningeal artery, combined with embolization of tumor-supplying vessels (196). Moreover, the median overall survival was effectively extended to 6 months in small-cell lung cancer patients with brain metastases receiving superselective intracranial arterial infusion chemotherapy (teniposide, ACNU, and carboplatin) (197) vs. 4–6 months of standard whole brain radiotherapy (198, 199). Therefore, carefully weighing beneficial outcomes vs. potential risks and adverse events is required for different brain tumor types. Additional comparison to system administration in further clinical trials is also warranted.

Advanced Imaging Technology

Advanced imaging technology is of great value for the diagnosis and treatment of brain tumors (Table 4). Originally, imaging technology was mainly used to detect the radioactivity of radiopharmaceuticals or contrast agents in order to reflect the distribution of drugs in tumor tissues. Later, imaging was used to guide the intra-arterial drug perfusion and to predict therapeutic effects. Dynamic PET imaging was first performed to determine the position of the superselective catheter by intra-arterial injection of ¹¹C-labeled BCNU, and to predict clinical response by comparing ¹¹C radioactivity within the tumor after SIACI vs. intravenous infusion (185). Similarly, continuous PET scans were performed to quantify the pharmacokinetic advantage of ¹³N-labeled cisplatin by calculating the time course of ¹³N activity in tumor and normal brain tissue (200). In addition, PET can distinguish between cerebral necrosis following supraophthalmic intra-arterial chemotherapy or radiotherapy (low metabolic turnover) and tumor recurrence (high metabolic turnover) using ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) (201). Glucose metabolism was also measured by PET imaging to evaluate early treatment effects of intra-arterial administration of ACNU into glioblastomas and astrocytomas (202), as well as recombinant human tumor necrosis factor (TNF)-alpha in malignant astrocytomas (203). Another non-invasive method using radiopharmaceutical labeling to monitor drug biodistribution in tumors for assessing the effectiveness of intra-arterial chemotherapy is dynamic scintigraphic imaging with ^195mPt-labeled cisplatin (206). Moreover, SPECT using ^99mTc-hexamethyl-propyleneamine oxime (HMPAO) allows one to evaluate the cerebral distribution after either fast pulsatile or slow continuous supraophthalmic carotid infusion (186). Using ^99mTc-hexakis-2-methoxyisobutyl-isonitrile (MIBI), SPECT can also assess changes in tumor MIBI uptake before and after radiochemotherapy (204).

The main limitation of SPECT and PET is the relatively low spatial resolution of these imaging modalities. CT is superior in this respect, has widespread availability, and is easier to apply. The permeability of blood vessels in brain tumors can be assessed in CT images by measuring iopamidol distribution in blood vessels and the extracellular fluid space (217). Angio-CT provides more accurate information on the vascular territory of the tumor than digital subtraction angiography (DSA), which aids intra-arterial chemotherapy of metastatic brain tumors (208). Superselective angio-CT was also shown to precisely define enlarged medullary veins in patients suffering from astrocytomas (207). Recently, direct-current (DC)-EEG was applied for real-time, non-invasive monitoring of BBB opening during clinical treatment of a primary CNS lymphoma by measuring low frequency oscillations of 0.01–0.15 Hz (16), but the accuracy of the procedure needs to be verified.

With the widespread availability of MRI, the intra-arterial administration of therapeutic drugs to brain tumors is further improved. Due to its high resolution and sensitivity, MRI has the ability to accurately assess the therapeutic response to the tumors. Magnetic resonance spectroscopy (MRS) is used to reveal intracellular pH changes after BCNU treatment for anaplastic astrocytomas or glioblastomas with alkalization in intra-arterial administration and acidification in intravenous chemotherapy (209). The reduction of phosphocreatine and phosphodiesters, indicating early metabolic changes after intra-arterial treatment, can be visualized by MRS imaging and precedes apparent structural changes (210). Recently, proton MRS was successfully applied to detect a decreased total cholesterol (tCho)/α-naphtalene acetic acid (NAA) metabolite ratio. tCho is used as a marker for cell membrane breakdown and proliferation, while NAA indicates neuronal density and viability. The decreased tCho/NAA ratio was observed in two regions of interest (enhancing component and non-enhancing T2-hyperintense signal abnormality) after SIACI of bevacizumab in the treatment of recurrent grade IV glioblastoma (194). By measuring biochemical changes rather than detecting anatomical abnormalities, MRS avoids the non-specific reduction of MRI contrast enhancement by bevacizumab, while providing potential biomarkers of treatment efficacy (194). However, these preliminary studies lack a precise description of clinically meaningful endpoints, which are urgently needed for the long-term follow-up of larger patient populations to determine the correlation of early metabolic changes with treatment outcomes.

MRI usually determines the changes in tumor volume by measuring the size of the contrast-enhanced lesion. However, given that both recurrent tumors and therapeutic drugs may cause BBB destruction leading to heterogeneous enhancement and T2/FLAIR hyperintensity, MRI has limitations in distinguishing between tumor recurrence and long-lasting sequelae of the therapeutic intervention. To overcome this deficiency, hemodynamic changes in tumors are considered an important indicator to accurately predict disease progression. Originally, MR DSA following bolus injection of gadolinium chelates offers a high temporal resolution for showing large cerebral arteries, venous sinuses, and tumor blood vessels. In some doubtful cases, MR DSA was able to identify meningioma and acoustic neuroma by first-pass stain. The tumors were later confirmed by pathological examination (211). Next, dynamic susceptibility contrast MR imaging (DSC-MRI) became a more common MRI perfusion technique. It can reveal cerebral blood volume, cerebral blood flow, and mean transit time for assessing brain tumors by using gadolinium-based tracer kinetic and dilution models (218). MRI with gadolinium was recently used to provide a better visualization of ambiguous tumor feeding arteries during microcatheter injection of bevacizumab in treating a recurrent butterfly glioblastoma, underlining the role of MRI in real-time guidance of neurointervention (212).

However, use of gadolinium-based agents is associated with a potential risk for brain deposition and nephrogenic systemic fibrosis (219). Chemical exchange saturation transfer (CEST), a new contrasting strategy, can apply a saturation pulse to the resonance frequency of the exchange protons on the compound to sensitively detect perfusion area and BBB opening. Salicylic acid analogs (SAA) are the natural contrast agents used for CEST MRI and may offer increased safety and operability than gadolinium-based agents (55). In recent years, 3D pseudo-continuous arterial spin labeling (3D-pcASL), a non-invasive MR perfusion measurement technique not requiring contrast injection, has been found to provide higher image quality with less susceptibility artifacts than DSC-MRI. Cerebral blood volume and flow measured by DSC-MRI or 3D-pcASL are different between patients with tumor recurrence and those who experience long-lasting treatment effects (220). However, image distortion still occurs in inhomogeneous regions. To address this, the combination of 3D-pcASL and Turbo Spin Echo using Cartesian acquisition with spiral profile reordering was used to provide better contrast between tumor and normal tissues. Another benefit is high reproducibility between scanning sessions, suggesting a potential use for therapeutic response assessment (221).

MRI monitoring and magnetic targeting also play an important role for intra-arterial drug delivery systems. A prominent example is highly selective deposition of magnetic microparticles in brain tumors (Table 3). In the late 1980s, large multivesicular liposomes containing magnetic resonance contrast agents were found to spontaneously attach to the vascular bed of vessels in the frontal and occipital lobe when injected intra-arterially into experimental animals (222). Currently, intravenously infused iron oxide nanoparticles can be selectively deposited in gliosarcomas when using a low-strength magnetic field (0.4 T) (223). The short plasma half-lives of magnetic nanoparticles make them more suitable for intra-arterial infusion (224). However, administering large numbers of magnetic particles into cerebral arteries is associated with a considerable risk of embolization (225). The precision of the approach can be increased by modifying magnetic field topography, thereby alleviating the above-mentioned risk of embolism (166). Further, the cationized model protein β-galactosidase (representing targeted protein drugs such as tumor suppressor proteins and anti-neoplastic enzymes) loaded onto heparin-coated iron-oxide nanoparticles could be precisely deposited in glioma tissue by intra-arterial infusion under MRI surveillance. This also allowed for optimization of magnetic field topography and maintained physiological arterial fluid dynamics, thus representing an effective approach for precise molecular treatment of brain tumors (167). In terms of cell transplantation, MRI enables real-time tracking of bone marrow-derived human mesenchymal stem cells (MSCs) labeled with superparamagnetic nanoparticles (216) or human MSCs expressing ferritin heavy chains (215) in experimental animals (Table 4). In addition, MRI may help to avoid adverse ischemic events in the clinical treatment of glioblastoma multiforme by intra-arterial infusion of tumor-infiltrating lymphocytes. This notion is supported by preclinical data showing that MRI is well-suited to evaluate ischemic events during intra-arterial infusion of activated T cells into the native rabbit brain (226).

Other Approaches

There are a number of other approaches to improve intra-arterial administration. The first approach is the combination of compounds to enhance the efficacy of chemotherapeutic drugs. For instance, it was shown that the combination of oral 2% D, L-alpha-difluoromethylornithine and intra-arterial injection of BCNU doubled the median survival time of T9 gliosarcoma-bearing rats by reducing polyamine metabolism required for tumor growth and enhancing anti-tumor cytotoxicity of BCNU (227). Spirohydantoin mustard (spiromustine) promotes BBB penetration and cisplatin deposition in glioblastoma multiforme by combining the anti-tumor reactive moiety of cisplatin with the hydantoin part of spiromustine (228). However, the neurotoxicity of these compounds hampers the interest in further research.

The second approach is the combination of multiple therapeutic regimens. For example, intra-carotid administration of cisplatin combined with intravenous doxorubicin injection is an alternative treatment for patients with inoperable meningiomas (229). Short-term intra-arterial and intravenous chemotherapy prior to radiation increases survival of adult patients with astrocytomas (230). Hyperthermia enhances the cytotoxic effects and deposition of anti-cancer drugs to the tumors. Both preclinical and clinical studies showed that ACNU (231) or adriamycin (232, 233) delivery in combination with local or interstitial brain hyperthermia was associated with higher survival rates. Moreover, intra-arterial administration of carboplatin and melphalan combined with intrathecal topotecan chemotherapy showed a good alleviation effect on a patient suffering from extraocular retinoblastoma with CNS involvement (234). Of note, such combined therapy is often based on individualized treatments. This requires consideration of various factors such as radio- or chemotherapy sensitivity of the tumors, invasion area, and metastatic pathways.

The third approach is the use of new therapeutic agents. Injection of bromodeoxyuridine (anaerobic radiosensitizer) into the external carotid artery through a catheter has been found to increase susceptibility of glioma cells to radiotherapy and increases survival time of treated patients (235). Moreover, intra-carotid injection of recombinant human TNF and lymphotoxin produces remarkable anti-tumor effects in C6 and T9 gliomas-bearing animal models (236). Clinically, intra-arterial administration of TNF-alpha improves the neurological symptoms in patients with glioblastoma multiforme or malignant astrocytomas by inducing coagulation necrosis in central tumor tissue and its feeding arteries (237). With the same strategy, advanced cytotoxins consisting of IL-13, IL-4 or transforming growth factor-alpha have been developed to target glioblastomas expressing these receptors (144, 238, 239). In general, data regarding the efficacy of these cytotoxins is less encouraging when applied in solid tumors. This may be due to the difficulties of large molecules to penetrate the tumor mass, and lower or more variable receptor expression in solid neoplasms.

The fourth approach is gene therapy. Intra-arterial infusion of a p53-containing adenoviral vector can delay the growth of Gli36 glioblastoma tissue carrying a missense-mutated p53 gene (240). Phosphorothioate oligodeoxynucleosides injected intra-arterially were precisely delivered to tumor tissue after BBB opening with bradykinin (241). Recently, intra-arterial infusion of a plasmid encoding an anti-angiogenic endostatin was shown to prolong survival time in the rat 9L gliosarcoma model by decreasing tumor vascular density, perfusion, and permeability (242). Moreover, G47Delta viruses (herpes simplex virus vector with oncolytic replication-competency) carrying deletions of the gamma34.5 and alpha47 genes (243) or the CLN2 gene (244) were injected into the carotid artery after mannitol-mediated BBB opening and had a positive impact on survival in a nude mouse model of cerebral breast cancer metastasis. A recent Phase II clinical trial showed that intra-arterial administration of ganciclovir combined with replication-deficient adenovirus mutant thymidine kinase is effective in improving 6-month progression-free survival, overall progression-free survival, and overall survival in patients with recurrent high-grade gliomas (anaplastic gliomas and glioblastomas) (245). Compared with intratumoral or intracerebral injections in current clinical trials (246, 247), intra-arterial gene therapy expands the treatment area and maximizes the therapeutic effect, but it also puts forward higher requirements for transfection efficiency.

The fifth approach is cell therapy that may benefit from intra-arterial administration. Intra-carotid rather than intravenous administration of a human cytotoxic T-cell line (TALL-104) in the 9L glioblastoma model and a metastatic xenograft model of epidermoid carcinoma enhanced specific anti-tumor effects and significantly prolonged survival time (248). Injection of a murine colon cancer cell line (CT-26) overexpressing interleukin-4 (IL-4) or hemagglutinin antigen can serve as a pre-immunization strategy to prevent metastases from cecum, liver, and lung. Intra-carotid but not systemic administration of CT-26 expressing IL-4 or hemagglutinin antigen is effective to prevent the growth of blood-borne brain metastases (249). In addition, cells may be good “vectors” to be used in intravascular gene therapy. Human MSCs carrying Delta24-RGD oncolytic adenoviruses and labeled with green fluorescent protein are selectively planted into glioma xenografts and exert a strong anti-tumor effect (250). However, it is still too early to translate these approaches into clinical applications.

Conclusions

This systematic review comprehensively describes existing strategies for promoting the accuracy of intra-arterial drug delivery in experimental and clinical brain tumor therapy (Figure 2). These strategies show a promising potential to innovate and optimize many aspects of brain tumor treatments, including the accurate prediction of targeted tumor tissue, the effectiveness of drug transfer over the BBB/BTB, and the precise deposition of the therapeutic agent(s) in the tumor. Moreover, methodological advances foster the development of multidisciplinary treatment strategies that can result in better treatment effects and might represent a promising way forward in the treatment of brain tumors. However, translating new and improved methods from animal experiments to clinical practice still has to face many challenges. First, genetic, molecular, immune, and cellular differences between humans and other species prevent animal models from replicating the whole spectrum of important aspects of human pathophysiology under disease-specific conditions. Second, experimental animals exhibit different tolerances to drug toxicity, which makes it difficult to accurately assess the safety and effectiveness of therapeutic or adjuvant drugs before applying them to patients. Third, the number of patients included in early-stage clinical trials is usually insufficient to reveal all but the strongest effects, while patient age, sex, tumor type, course of disease, and adjunct treatment strategies are difficult to standardize or even harmonize. This limits the predictive value of obtained results. Based on this, new disease models have attracted much interest. The “tumor graft models” or “patient-derived xenograft” models are valuable humanized models to maintain the tumor heterogeneity and genetic characteristics of the patients by implanting tumor tissues removed from surgery into immunodeficient mice. Another breakthrough is the development of human brain organoids, which can be produced by patient-derived tumor cells or tissues in a 3D in-vitro culture system. These organoids have greater feasibility in large-scale screening of therapeutic agents and can exhibit their aggressiveness and proliferative ability and establish vascular system in host brains. In addition, some large animals exhibit an anatomical structure of the brain and its blood vessels being similar to that of humans, which may be a good option to optimize intra-arterial procedures. These models can also make excellent use of clinical imaging technologies (251). Taken together, this forms an excellent basis to further refine intra-arterial approaches for the treatment of brain tumors to ultimately improve clinical treatment regimens.

Figure 2

References

• 1.

  de RoblesPFiestKMFrolkisADPringsheimTAttaCst. Germaine-SmithCet al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. (2015) 17:776–83. 10.1093/neuonc/nou283

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 2.

  OstromQTGittlemanHTruittGBosciaAKruchkoCBarnholtz-SloanJS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. (2018) 20:iv1–86. 10.1093/neuonc/noy131

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 3.

  FoxBDCheungVJPatelAJSukiDRaoG. Epidemiology of metastatic brain tumors. Neurosurg Clin North Am. (2011) 22:1–6. 10.1016/j.nec.2010.08.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 4.

  CagneyDNMartinAMCatalanoPJRedigAJLinNULeeEQet al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. (2017) 19:1511–21. 10.1093/neuonc/nox077

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 5.

  Miranda-FilhoAPinerosMSoerjomataramIDeltourIBrayF. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. (2017) 19:270–80. 10.1093/neuonc/now166

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 6.

  McNeillKA. Epidemiology of brain tumors. Neurol Clin. (2016) 34:981–98. 10.1016/j.ncl.2016.06.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 7.

  ShahVKocharP. Brain cancer: implication to disease, therapeutic strategies and tumor targeted drug delivery approaches. Recent Pat Anticancer Drug Discov. (2018) 13:70–85. 10.2174/1574892812666171129142023

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 8.

  PerkinsALiuG. Primary brain tumors in adults: diagnosis and treatment. Am Fam Physician. (2016) 93:211–7.

  • Google Scholar
  • View reference in article

• 9.

  RockKMcArdleOFordePDunneMFitzpatrickDO'NeillBet al. A clinical review of treatment outcomes in glioblastoma multiforme–the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?Br J Radiol. (2012) 85:e729–33. 10.1259/bjr/83796755

  • CrossRef
  • Google Scholar
  • View reference in article

• 10.

  DwivediNShahJMishraVMohd AminMCIyerAKTekadeRKet al. Dendrimer-mediated approaches for the treatment of brain tumor. J Biomater Sci Polym Ed. (2016) 27:557–80. 10.1080/09205063.2015.1133155

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 11.

  TheodotouCShahAHHayesSBregyAJohnsonJNAziz-SultanMAet al. The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. Br J Neurosurg. (2014) 28:438–46. 10.3109/02688697.2013.877122

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 12.

  FrenchJDWestPMVon AmerongenFKMagounHW. Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J Neurosurg. (1952) 9:378–89. 10.3171/jns.1952.9.4.0378

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 13.

  CookeJNEllisJAHossainSNguyenJBruceJNJoshiS. Computational pharmacokinetic rationale for intra-arterial delivery to the brain. Drug Deliv Transl Res. (2016) 6:622–9. 10.1007/s13346-016-0319-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 14.

  FaltingsLKulasonKOPatelNVWongTFralinSLiMet al. Rechallenging recurrent glioblastoma with intra-arterial bevacizumab with blood brain-barrier disruption results in radiographic response. World Neurosurg. (2019) 131:234–41. 10.1016/j.wneu.2019.07.137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 15.

  BianciottoCShieldsCLIturraldeJCSariciAJabbourPShieldsJA. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology. (2012) 119:843–9. 10.1016/j.ophtha.2011.09.040

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 16.

  KiviniemiVKorhonenVKortelainenJRytkySKeinanenTTuovinenTet al. Real-time monitoring of human blood-brain barrier disruption. PLoS ONE. (2017) 12:e0174072. 10.1371/journal.pone.0174072

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 17.

  MahaleyMSJrHippSWDropchoEJBertschLCushSTireyTet al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg. (1989) 70:371–8. 10.3171/jns.1989.70.3.0371

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 18.

  AssiettiROlsonJJ. Intra-arterial cisplatin in malignant brain tumors: incidence and severity of otic toxicity. J Neurooncol. (1996) 27:251–8. 10.1007/BF00165482

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 19.

  HochbergFHPruittAABeckDODeBrunGDavisK. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg. (1985) 63:876–80. 10.3171/jns.1985.63.6.0876

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 20.

  BashirRHochbergFHLinggoodRMHottlemanK. Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. J Neurosurg. (1988) 68:917–9. 10.3171/jns.1988.68.6.0917

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 21.

  SonodaYMatsumotoKKakutoYNishinoYKumabeTTominagaTet al. Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy. Acta Neurochir. (2007) 149:1183–9. discussion: 1189. 10.1007/s00701-007-1277-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 22.

  AshbyLSShapiroWR. Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol. (2001) 51:67–86. 10.1023/a:1006441104260

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 23.

  DropchoEJRosenfeldSSMorawetzRBVitekJBrothersMGorumTet al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium. J Clin Oncol. (1992) 10:452–8. 10.1200/JCO.1992.10.3.452

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 24.

  MortimerJECrowleyJEyreHWeidenPEltringhamJStuckeyWJ. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study. Cancer. (1992) 69:1220–3. 10.1002/cncr.2820690525

  • CrossRef
  • Google Scholar
  • View reference in article

• 25.

  StewartDJBelangerJMEGGrahovacZCuruvijaSGionetLRAitkenSEet al. Phase I study of intracarotid administration of carboplatin. Neurosurgery. (1992) 30:512–7. 10.1227/00006123-199204000-00007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 26.

  TfayliAHentschelPMadajewiczSManzioneJChowhanNDavisRet al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol. (1999) 42:73–7.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 27.

  FigueiredoEGFariaJWTeixeiraMJ. Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. Arq Neuropsiquiatr. (2010) 68:778–82. 10.1590/S0004-282X2010000500020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 28.

  ShapiroWRGreenSBBurgerPCSelkerRGVanGilderJCRobertsonJTet al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. (1992) 76:772–81. 10.3171/jns.1992.76.5.0772

  • CrossRef
  • Google Scholar
  • View reference in article

• 29.

  KochiiMKitamuraIGotoTNishiTTakeshimaHSaitoYet al. Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol. (2000) 49:63–70.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 30.

  NewtonHB. Intra-arterial chemotherapy of primary brain tumors. Curr Treat Opt Oncol. (2005) 6:519–30. 10.1007/s11864-005-0030-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 31.

  ImbesiFMarchioniEBenericettiEZappoliFGalliACoratoMet al. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res. (2006) 26:553–8.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 32.

  PardridgeWM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. (2005) 2:3–14. 10.1602/neurorx.2.1.3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 33.

  AbbottNJPatabendigeAADolmanDEYusofSRBegleyDJ. Structure and function of the blood-brain barrier. Neurobiol Dis. (2010) 37:13–25. 10.1016/j.nbd.2009.07.030

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 34.

  BhowmikAKhanRGhoshMK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. (2015) 2015:320941. 10.1155/2015/320941

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 35.

  PapademetriouITPorterT. Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv. (2015) 6:989–1016. 10.4155/tde.15.48

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 36.

  ChowBWGuC. The molecular constituents of the blood-brain barrier. Trends Neurosci. (2015) 38:598–608. 10.1016/j.tins.2015.08.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 37.

  ObermeierBDanemanRRansohoffRM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. (2013) 19:1584–96. 10.1038/nm.3407

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 38.

  MeewesCBohuslavizkiKHKrischBHeld-FeindtJHenzeEClausenM. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas. J Nucl Med. (2001) 42:1338–45.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 39.

  AmmounSHanemannCO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol. (2011) 7:392–9. 10.1038/nrneurol.2011.82

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 40.

  DhermainFGHauPLanfermannHJacobsAHvan den BentMJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. (2010) 9:906–20. 10.1016/S1474-4422(10)70181-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 41.

  van TellingenOYetkin-ArikBde GooijerMCWesselingPWurdingerTde VriesHE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. (2015) 19:1–12. 10.1016/j.drup.2015.02.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 42.

  LamszusKLaterraJWestphalMRosenEM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. (1999) 17:517–30. 10.1016/S0736-5748(99)00008-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 43.

  HiesigerEMVoorhiesRMBaslerGA. Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol. (1986) 19:50–9. 10.1002/ana.410190110

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 44.

  CosoloWChristophidisN. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats. Cancer Res. (1987) 47:6225–8.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 45.

  InoueTFukuiMNishioSKitamuraKNagaraH. Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. J Neurosurg. (1987) 66:256–63. 10.3171/jns.1987.66.2.0256

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 46.

  ShapiroWRVoorhiesRMHiesigerEMSherPBBaslerGALipschutzLE. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. Cancer Res. (1988) 48:694–701.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 47.

  BarthRFYangWRotaruJHMoeschbergerMLBoeselCPSolowayAHet al. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiat Oncol Biol Phys. (2000) 47:209–18. 10.1016/S0360-3016(00)00421-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 48.

  BarthRFYangWRotaruJHMoeschbergerMLJoelDDNawrockyMMet al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. (1997) 57:1129–36.

  • Google Scholar
  • View reference in article

• 49.

  HsiehCHChenYFChenFDHwangJJChenJCLiuRSet al. Evaluation of pharmacokinetics of 4-borono-2-F-18-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. J Nucl Med. (2005) 46:1858–65.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 50.

  YangWBarthRFCarpenterDEMoeschbergerMLGoodmanJH. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery. (1996) 38:985–92. 10.1097/00006123-199605000-00027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 51.

  YangWBarthRFRotaruJHBoeselCPWilkieDABresnahanJCet al. Boron neutron capture therapy of brain tumors: functional and neuropathologic effects of blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. J Neuro Oncol. (2000) 48:179–90. 10.1023/a:1006410611067

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 52.

  YangWBarthRFRotaruJHMoeschbergerMLJoelDDNawrockyMMet al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood- brain barrier disruption. Int J Radiat Oncol Biol Phys. (1997) 37:663–72. 10.1016/S0360-3016(96)00082-X

  • CrossRef
  • Google Scholar
  • View reference in article

• 53.

  NeuweltEABarnettPAMcCormickCIRemsenLGKrollRASextonG. Differential permeability of a human brain tumor xenograft in the nude rat: impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res. (1998) 4:1549–55.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 54.

  RemsenLGTrailPAHellstromIHellstromKENeuweltEA. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery. (2000) 46:704–9. 10.1097/00006123-200003000-00034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 55.

  SongXWalczakPHeXYangXPearlMJBulteJWMet al. Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion. J Cereb Blood Flow Metab. (2016) 36:1186–94. 10.1177/0271678X16637882

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 56.

  BullardDEBignerDD. Blood-brain barrier disruption in immature Fischer 344 rats. J Neurosurg. (1984) 60:743–50. 10.3171/jns.1984.60.4.0743

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 57.

  InamuraTBlackKL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab. (1994) 14:862–70. 10.1038/jcbfm.1994.108

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58.

  NomuraTInamuraTBlackKL. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. (1994) 659:62–6. 10.1016/0006-8993(94)90863-X

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 59.

  InamuraTNomuraTBartusRTBlackKL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. (1994) 81:752–8. 10.3171/jns.1994.81.5.0752

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 60.

  BartusRTElliottPJDeanRLHaywardNJNagleTLHuffMRet al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol. (1996) 142:14–28. 10.1006/exnr.1996.0175

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61.

  MatsukadoKInamuraTNakanoSFukuiMBartusRTBlackKL. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery. (1996) 39:125–33. discussion: 133–24. 10.1097/00006123-199607000-00025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 62.

  MatsukadoKNakanoSBartusRTBlackKL. Steroids decrease uptake of carboplatin in rat gliomas–uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J Neuro Oncol. (1997) 34:131–8. 10.1007/978-3-7091-6837-0_48

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 63.

  NakanoSMatsukadoKBlackKL. Enhanced cytokines delivery and intercellular adhesion molecule 1 (ICAM-1) expression in glioma by intracarotid infusion of bradykinin analog, RMP-7. Neurol Res. (1997) 19:501–8. 10.1080/01616412.1997.11740848

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 64.

  BarnettFHRainovNGIkedaKSchubackDEElliottPKrammCMet al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. (1999) 6:14–20. 10.1038/sj.cgt.7700003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 65.

  ErdlenbruchBJendrossekVEiblHLakomekM. Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats. Exp Brain Res. (2000) 135:417–22. 10.1007/s002210000553

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 66.

  ErdlenbruchBJendrossekVKuglerWEiblHLakomekM. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother Pharmacol. (2002) 50:299–304. 10.1007/s00280-002-0497-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 67.

  ErdlenbruchBAlipourMFrickerGMillerDSKuglerWEiblHet al. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol. (2003) 140:1201–10. 10.1038/sj.bjp.0705554

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 68.

  ErdlenbruchBSchinkhofCKuglerWHeinemannDEHHermsJEiblHet al. (2003). Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol. 139:685–94. 10.1038/sj.bjp.0705302

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69.

  ErdlenbruchBKuglerWSchinkhofCNeurathHEiblHLakomekM. Blood-brain barrier opening with alkylglycerols: biodistribution of 1-O-pentylglycerol after intravenous and intracarotid administration in rats. J Drug Target. (2005) 13:143–50. 10.1080/10611860400029085

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70.

  InamuraTNomuraTIkezakiKFukuiMPollingerGBlackKL. Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma. Neurol Res. (1994) 16:125–8. 10.1080/01616412.1994.11740209

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71.

  MatsukadoKNomuraTIkezakiKFukuiM. Selective increase in blood-tumor barrier permeability by calcium antagonists in transplanted rat brain tumors. Acta Neurochirurg Suppl. (1994) 60:403–5. 10.1007/978-3-7091-9334-1_109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 72.

  SpigelmanMKZappullaRAGoldbergJDGoldsmithSJMarottaDMalisLIet al. Effect of intracarotid etoposide on opening the blood-brain barrier. Cancer Drug Deliv. (1984) 1:207–11. 10.1089/cdd.1984.1.207

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 73.

  SugimotoSYamamotoYLNagahiroSDiksicM. Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats. J Neuro Oncol. (1995) 24:229–40. 10.1007/BF01052839

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 74.

  Mouchard-DelmasCGourdierBVistelleRWiczewskiM. Modification of the blood-brain barrier permeability following intracarotid infusion of vinorelbine. Anticancer Res. (1995) 15:2593–6.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 75.

  BlackKLKingWAIkezakiK. Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4. J Neurosurg. (1990) 72:912–6. 10.3171/jns.1990.72.6.0912

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 76.

  ChioCCLinSJLinMT. Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats. J Neuro Oncol. (1995) 25:89–95. 10.1007/BF01057752

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77.

  AbrahamCSDeliMAJooFMegyeriPTorpierG. Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. Neurosci Lett. (1996) 208:85–8. 10.1016/0304-3940(96)12546-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78.

  WeyerbrockAWalbridgeSPlutaRMSaavedraJEKeeferLKOldfieldEH. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg. (2003) 99:728–37. 10.3171/jns.2003.99.4.0728

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 79.

  WangZ-HXueYXLiuYH. The modulation of protein kinase A and heat shock protein 70 is involved in the reversible increase of blood-brain tumor barrier permeability induced by papaverine. Brain Res Bull. (2010) 83:367–73. 10.1016/j.brainresbull.2010.08.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 80.

  NeuweltEAHillSAFrenkelEPDiehlJTMaravillaKRVuLHet al. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Cancer Treat Rep. (1981) 65(Suppl. 2):39–43.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 81.

  RapoportSI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol. (2000) 20:217–30. 10.1023/a:1007049806660

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 82.

  SiegalTRubinsteinRBoksteinFSchwartzALossosAShalomEet al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg. (2000) 92:599–605. 10.3171/jns.2000.92.4.0599

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 83.

  FredericksWRRapoportSI. Reversible osmotic opening of the blood-brain barrier in mice. Stroke. (1988) 19:266–8. 10.1161/01.STR.19.2.266

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 84.

  PollayM. Effect of hypertonic solutions on the blood-brain barrier. Neurology. (1975) 25:852–6. 10.1212/WNL.25.9.852

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85.

  BonstelleCTKoriSHRekateH. Intracarotid chemotherapy of glioblastoma after induced blood-brain barrier disruption. AJNR Am J Neuroradiol. (1983) 4:810–2.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 86.

  NeuweltEAHowiesonJFrenkelEPSpechtHDWeigelRBuchanCGet al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery. (1986) 19:573–82. 10.1227/00006123-198610000-00011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 87.

  HeimbergerKSamecPBinderHPodrekaIReisnerTDeeckeLet al. Blood brain barrier modification and chemotherapy. Interv Neuroradiol. (1986) 369:223–6.

  • Pubmed Abstract
  • Google Scholar
  • View reference in article

• 88.

  HoriTMuraokaKSaitoYSasaharaKInagakiHInoueYet al. Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors. J Neurosurg. (1987) 66:372–8. 10.3171/jns.1987.66.3.0372

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 89.

  NeuweltEADahlborgSA. Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neuro Oncol. (1987) 4:195–207. 10.1007/BF00150611

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90.

  MiyagamiMTsubokawaTTazoeMKagawaY. Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumors. Neurol Medico Chirurgica. (1990) 30:582–90. 10.2176/nmc.30.582

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 91.

  MarkowskySJZimmermanCLThollDSoriaICastilloR. Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monitor. (1991) 13:24–31. 10.1097/00007691-199101000-00002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 92.

  IwadateYNambaHSaegusaTSueyoshiK. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors. J Neuro Oncol. (1993) 15:185–93. 10.1007/BF01053940

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 93.

  FortinDGendronCBoudriasMGarantMP. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer. (2007) 109:751–60. 10.1002/cncr.22450

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 94.

  DoolittleNDMinerMEHallWASiegalTHansonEJOsztieEet al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. (2000) 88:637–47. 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 95.

  FortinDDesjardinsABenkoANiyonsegaTBoudriasM. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer. (2005) 103:2606–15. 10.1002/cncr.21112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 96.

  JahnkeKKraemerDFKnightKRFortinDBellSDoolittleNDet al. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer. (2008) 112:581–8. 10.1002/cncr.23221

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 97.

  GuillaumeDJDoolittleNDGahramanovSHedrickNADelashawJBNeuweltEA. Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery. (2010) 66:48–58. discussion: 58. 10.1227/01.NEU.0000363152.37594.F7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar
  • View reference in article

• 98.

  AngelovLDoolittleNDKraemerDFSiegalTBarnettGHPeereboomDMet al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. (2009) 27:3503–9. 10.1200/JCO.2008.19.3789

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99.

  Zylber-KatzEGomoriJMSchwartzALossosABoksteinFSiegalT. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther. (2000) 67:631–41. 10.1067/mcp.2000.106932

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100.

  BoockvarJATsiourisAJHofstetterCPKovanlikayaIFralinSKesavabhotlaKet al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma Clinical article. J Neurosurg. (2011) 114:624–32. 10.3171/2010.9.JNS101223

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101.

  BurkhardtJKRiinaHShinBJChristosPKesavabhotlaKHofstetterCPet al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg. (2012) 77:130–4. 10.1016/j.wneu.2011.05.056

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102.

  ChakrabortySFilippiCGBurkhardtJKFralinSRayAWongTet al. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma. J Exp Ther Oncol. (2016) 11:261–7.

  • Pubmed Abstract
  • Google Scholar

• 103.

  RiinaHAFraserJFFralinSKnopmanJScheffRJBoockvarJA. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol. (2009) 8:145–50.

  • Pubmed Abstract
  • Google Scholar

• 104.

  RiinaHAKnopmanJGreenfieldJPFralinSGobinYPTsiourisAJet al. Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. Interv Neuroradiol. (2010) 16:71–6. 10.1177/159101991001600109

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105.

  ShinBJBurkhardtJ-KRiinaHABoockvarJA. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin North Am. (2012) 23:323. 10.1016/j.nec.2012.01.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106.

  RajappaPKrassJRiinaHABoockvarJAGreenfieldJP. Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. Interv Neuroradiol. (2011) 17:459–65. 10.1177/159101991101700410

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107.

  ChakrabortySFilippiCGWongTRayAFralinSTsiourisAJet al. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. J Neuro Oncol. (2016) 128:405–15. 10.1007/s11060-016-2099-8

  • CrossRef
  • Google Scholar

• 108.

  KulasonKOSchneiderJRChakrabortySFilippiCGPramanikBWongTet al. Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma. J Exp Ther Oncol. (2018) 12:223–9.

  • Pubmed Abstract
  • Google Scholar

• 109.

  BlackKLCloughesyTHuangSCGobinYPZhouYGrousJet al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg. (1997) 86:603–9. 10.3171/jns.1997.86.4.0603

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110.

  CloughesyTFBlackKLGobinYPFarahaniKNelsonGVillablancaPet al. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery. (1999) 44:270–8. discussion: 278–9. 10.1097/00006123-199902000-00015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111.

  ChowKLGobinYPCloughesyTSayreJWVillablancaJPViñuelaF. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol. (2000) 21:471–8.

  • Pubmed Abstract
  • Google Scholar

• 112.

  QureshiAISuriMFKhanJSharmaMOlsonKGutermanLRet al. Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J Neurooncol. (2001) 51:151–8. 10.1023/A:1010683128853

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113.

  JahnkeKKraemerDFFortinDBellSDoolittleNDKnightKRet al. Intra-arterial chemotherapy and osmotic blood-brain barrier disruption for primitive neuroectodermal tumors. J Clin Oncol. (2007) 25:581–8. 10.1200/jco.2007.25.18_suppl.2046

  • CrossRef
  • Google Scholar

• 114.

  JoshiSErginAWangMReifRZhangJBruceJNet al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol. (2011) 104:11–9. 10.1007/s11060-010-0466-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115.

  GroothuisDRWarknePCMolnarPLapinGDMikhaelMA. Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors. J Neurosurg. (1990) 72:441–9. 10.3171/jns.1990.72.3.0441

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116.

  FieschiCLenziGLZanetteEOrziFPasseroS. Effects on EEG of the osmotic opening of the blood-brain barrier in rats. Life Sci. (1980) 27:239–43. 10.1016/0024-3205(80)90143-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117.

  MarchiNAngelovLMasarykTFazioVGranataTHernandezNet al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia. (2007) 48:732–42. 10.1111/j.1528-1167.2007.00988.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118.

  ElkassabanyNMBhatiaJDeogaonkarABarnettGHLottoMMaurtuaMet al. Perioperative complications of blood brain barrier disruption under general anesthesia: a retrospective review. J Neurosurg Anesthesiol. (2008) 20:45–8. 10.1097/ANA.0b013e31815d5f1f

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119.

  IkedaMBhattacharjeeAKKondohTNagashimaTTamakiN. Synergistic effect of cold mannitol and Na+/Ca2+ exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun. (2002) 291:669–74. 10.1006/bbrc.2002.6495

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120.

  KayaMGulturkSElmasLKalayciRAricanNKocyildizZCet al. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Life Sci. (2004) 76:201–12. 10.1016/j.lfs.2004.07.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121.

  SchlageterKEMolnarPLapinGDGroothuisDR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res. (1999) 58:312–28. 10.1006/mvre.1999.2188

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122.

  NingarajNSRaoMHashizumeKAsotraKBlackKL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. (2002) 301:838–51. 10.1124/jpet.301.3.838

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123.

  NakanoSMatsukadoKBlackKL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res. (1996) 56:4027–31.

  • Pubmed Abstract
  • Google Scholar

• 124.

  SugitaMHuntGELiuYBlackKL. Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin. Neurol Res. (1998) 20:559–63. 10.1080/01616412.1998.11740564

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125.

  RainovNGDobbersteinKUHeideckeVDorantUChaseMKrammCMet al. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther. (1998) 5:158–62.

  • Pubmed Abstract
  • Google Scholar

• 126.

  BartusRT. Use of Cereport (TM) (RMP-7) to increase delivery of carboplatin to gliomas: insight and parameters for intracarotid infusion via a single-lumen cannula. Drug Delivery. (1999) 6:15–21. 10.1080/107175499267110

  • CrossRef
  • Google Scholar

• 127.

  RainovNGZimmerCChaseMKrammCMChioccaEAWeisslederRet al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Human Gene Ther. (1995) 6:1543–52. 10.1089/hum.1995.6.12-1543

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128.

  FordJOsbornCBartonTBleehenNM. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer. (1998) 34:1807–11. 10.1016/S0959-8049(98)00155-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129.

  EmerichDFSnodgrassPDeanRAgostinoMHaslerBPinkMet al. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer. (1999) 80:964–70. 10.1038/sj.bjc.6690450

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130.

  PradosMDScholdSCJrFineHAJaeckleKHochbergFMechtlerLet al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol. (2003) 5:96–103. 10.1093/neuonc/5.2.96

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131.

  SamalaRThorsheimHRGodaSTaskarKGrilBSteegPSet al. Vinorelbine delivery and efficacy in the MDA-MB-231BR preclinical model of brain metastases of breast cancer. Pharm Res. (2016) 33:2904–19. 10.1007/s11095-016-2012-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132.

  NewtonHBPageMAJunckLGreenbergHS. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol. (1989) 7:39–45. 10.1007/BF00149377

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133.

  NewtonHBSlivkaMAVolpiCBourekasECChristoforidisGABaujanMAet al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neurooncol. (2003) 61:35–44. 10.1023/A:1021218207015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 134.

  HeGXiaoXZouMZhangCXiaS. Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: a case report and literature review. Medicine. (2016) 95:e4401. 10.1097/MD.0000000000004401

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135.

  JahangiriAChinATFlaniganPMChenRBankiewiczKAghiMK. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg. (2017) 126:191–200. 10.3171/2016.1.JNS151591

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136.

  StineCAMunsonJM. Convection-enhanced delivery: connection to and impact of interstitial fluid flow. Front Oncol. (2019) 9:966. 10.3389/fonc.2019.00966

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137.

  KunwarSPradosMDChangSMBergerMSLangFFPiepmeierJMet al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. (2007) 25:837–44. 10.1200/JCO.2006.08.1117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138.

  LaskeDWYouleRJOldfieldEH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. (1997) 3:1362–8. 10.1038/nm1297-1362

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139.

  ShiMFortinDSancheLPaquetteB. Convection-enhancement delivery of platinum-based drugs and Lipoplatin™ to optimize the concomitant effect with radiotherapy in F98 glioma rat model. Investig New Drugs. (2015) 33:555–63. 10.1007/s10637-015-0228-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140.

  WhiteEBienemannATaylorHHopkinsKCameronAGillS. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp Clin Trials. (2012) 33:320–31. 10.1016/j.cct.2011.10.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141.

  CarpentierALaigle-DonadeyFZoharSCapelleLBehinATibiAet al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. (2006) 8:60–6. 10.1215/S1522851705000475

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142.

  KunwarSChangSMPradosMDBergerMSSampsonJHCroteauDet al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus. (2006) 20:E15.

  • Pubmed Abstract
  • Google Scholar

• 143.

  ShiMSancheL. Convection-enhanced delivery in malignant gliomas: a review of toxicity and efficacy. J Oncol. (2019) 2019:9342796. 10.1155/2019/9342796

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144.

  DebinskiWTatterSB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. (2009) 9:1519–27. 10.1586/ern.09.99

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145.

  HynynenK. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev. (2008) 60:1209–17. 10.1016/j.addr.2008.03.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146.

  HynynenKMcDannoldNVykhodtsevaNRaymondSWeisslederRJoleszFAet al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg. (2006) 105:445–54. 10.3171/jns.2006.105.3.445

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147.

  TreatLHMcDannoldNVykhodtsevaNZhangYTamKHynynenK. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. (2007) 121:901–7. 10.1002/ijc.22732

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148.

  MainprizeTLipsmanNHuangYMengYBethuneAIronsideSet al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a Clinical Safety and Feasibility Study. Sci Rep. (2019) 9:321. 10.1038/s41598-018-36340-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149.

  LiuHLHuaMYChenPYChuPCPanCHYangHWet al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. (2010) 255:415–25. 10.1148/radiol.10090699

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150.

  MeiJChengYSongYYangYWangFLiuYet al. Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imaging-guided focused ultrasound. J Ultrasound Med. (2009) 28:871–80. 10.7863/jum.2009.28.7.871

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151.

  McDannoldNClementGTBlackPJoleszFHynynenK. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery. (2010) 66:323–32. 10.1227/01.NEU.0000360379.95800.2F

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152.

  BuneviciusAMcDannoldNJGolbyAJ. Focused ultrasound strategies for brain tumor therapy. Oper Neurosurg. (2019) 19:9–18. 10.1093/ons/opz374

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 153.

  PulferSKGalloJM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target. (1998) 6:215–27. 10.3109/10611869808997896

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154.

  HanLRenYLongLZhongYShenCPuPet al. Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles. Oncol Rep. (2012) 27:121–8. 10.3892/or.2011.1459

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155.

  HuynhNTPassiraniCAllard-VannierELemaireLRouxJGarcionEet al. Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. Int J Pharm. (2012) 423:55–62. 10.1016/j.ijpharm.2011.04.037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156.

  ZhaoMChangJFuXLiangCLiangSYanRet al. Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats. J Drug Targeting. (2012) 20:416–21. 10.3109/1061186X.2011.651726

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157.

  CharestGSancheLFortinDMathieuDPaquetteB. Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. J Neuro Oncol. (2013) 115:365–73. 10.1007/s11060-013-1238-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158.

  JoshiSSingh-MoonRWangMChaudhuriDBEllisJABruceJNet al. Cationic surface charge enhances early regional deposition of liposomes after intracarotid injection. J Neuro Oncol. (2014) 120:489–97. 10.1007/s11060-014-1584-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159.

  JoshiSSingh-MoonRPWangMChaudhuriDBHolcombMStraubingerNLet al. Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue. J Neuro Oncol. (2014) 118:73–82. 10.1007/s11060-014-1421-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160.

  JoshiSSingh-MoonRPEllisJAChaudhuriDBWangMReifRet al. Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats. Neurosurgery. (2015) 76:92–100. 10.1227/NEU.0000000000000552

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161.

  Singh-MoonRPRoblyerDMBigioIJJoshiS. Spatial mapping of drug delivery to brain tissue using hyperspectral spatial frequency-domain imaging. J Biomed Opt. (2014) 19:096003. 10.1117/1.JBO.19.9.096003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162.

  JoshiSCookeJRChanDKEllisJAHossainSSSingh-MoonRPet al. Liposome size and charge optimization for intraarterial delivery to gliomas. Drug Deliv Transl Res. (2016) 6:225–33. 10.1007/s13346-016-0294-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163.

  NguyenJCookeJRNEllisJADeciMEmalaCWBruceJNet al. Cationizable lipid micelles as vehicles for intraarterial glioma treatment. J Neuro Oncol. (2016) 128:21–8. 10.1007/s11060-016-2088-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164.

  JoshiSJCookeRNEllisJAEmalaCWBruceJN. Targeting brain tumors by intra-arterial delivery of cell-penetrating peptides: a novel approach for primary and metastatic brain malignancy. J Neuro Oncol. (2017) 135:497–506. 10.1007/s11060-017-2615-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165.

  NguyenJHossainSSCookeJRNEllisJADeciMBEmalaCWet al. Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas. J Neuro Oncol. (2017) 133:77–85. 10.1007/s11060-017-2429-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166.

  ChertokBDavidAEYangVC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. (2011) 155:393–9. 10.1016/j.jconrel.2011.06.033

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167.

  ChertokBDavidAEYangVC. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials. (2011) 32:6245–53. 10.1016/j.biomaterials.2011.05.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168.

  WenCJZhangLWAl-SuwayehSAYenTCFangJY. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine. (2012) 7:1599–611. 10.2147/IJN.S29369

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169.

  CooperISassonKTeichbergVISchnaider-BeeriMFridkinMShechterY. Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins. J Biol Chem. (2012) 287:44676–83. 10.1074/jbc.M112.395384

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170.

  TangWFanWLauJDengLShenZChenX. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. (2019) 48:2967–3014. 10.1039/C8CS00805A

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171.

  DedrickRL. Arterial drug infusion: pharmacokinetic problems and pitfalls. J Natl Cancer Inst. (1988) 80:84–9. 10.1093/jnci/80.2.84

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172.

  SarisSCShookDRBlasbergRGDedrickRLDoppmanJLBankiewiczKSet al. Carotid artery mixing with diastole-phased pulsed drug infusion. J Neurosurg. (1987) 67:721–5. 10.3171/jns.1987.67.5.0721

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173.

  JoshiSWangMEtuJJNishanianEVPile-SpellmanJ. Cerebral blood flow affects dose requirements of intracarotid propofol for electrocerebral silence. Anesthesiology. (2006) 104:290–8. discussion: 295A. 10.1097/00000542-200602000-00014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174.

  WangMEtuJJoshiS. Enhanced disruption of the blood brain barrier by intracarotid mannitol injection during transient cerebral hypoperfusion in rabbits. J Neurosurg Anesthesiol. (2007) 19:249–56. 10.1097/ANA.0b013e3181453851

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175.

  EllisJACookeJSingh-MoonRPWangMBruceJNEmalaCWet al. Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. J Neuro Oncol. (2016) 130:449–54. 10.1007/s11060-016-2253-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176.

  SchemBCDahlO. Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma. J Neuro Oncol. (1991) 10:247–52. 10.1007/BF00177537

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177.

  NatoriYBabaTMoriguchiMTakeshitaIFukuiM. Effects of theophylline on the selective increases in intratumoral blood flow induced by intracarotid infusion of adenosine and adenosine triphosphate in C6 glioma-transplanted rat brains. Surg Neurol. (1992) 37:8–14. 10.1016/0090-3019(92)90058-U

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178.

  NomuraTIkezakiKNatoriYFukuiM. Altered response to histamine in brain tumor vessels: the selective increase of regional cerebral blood flow in transplanted rat brain tumor. J Neurosurg. (1993) 79:722–8. 10.3171/jns.1993.79.5.0722

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179.

  NomuraTIkezakiKMatsukadoKFukuiM. Effects of prostacyclin analogue iloprost on the regional cerebral blood flow in transplanted rat brain tumour. Neurol Res. (1993) 15:401–4. 10.1080/01616412.1993.11740172

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180.

  HashimotoTYoungWLAagaardBDJoshiSOstapkovichNDPile-SpellmanJet al. Adenosine-induced ventricular asystole to induce transient profound systemic hypotension in patients undergoing endovascular therapy. Dose Res Char Anesthesiol. (2000) 93:998–1001. 10.1097/00000542-200010000-00021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181.

  JoshiSWangMEtuJJSuckowRFCooperTBFeinmarkSJet al. Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol. (2008) 86:123–32. 10.1007/s11060-007-9450-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182.

  TheronJVillemureJGWorthingtonCTylerJL. Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiol Consider Neuroradiol. (1986) 28:118–25. 10.1007/BF00327882

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183.

  CharnsangavejCLeeYCarrascoCHFeunLGTangRAWrightKet al. Supraclinoid intracarotid chemotherapy using a flow-directed soft-tipped catheter. Radiology. (1985) 155:655–7. 10.1148/radiology.155.3.4001366

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184.

  KappJPRossRLTuckerEM. Supraophthalmic carotid infusion for brain-tumor chemotherapy. J Neurosurg. (1983) 58:616–8. 10.3171/jns.1983.58.4.0616

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185.

  TylerJLYamamotoYLDiksicMTheronJVillemureJGWorthingtonCet al. Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med. (1986) 27:775–80.

  • Pubmed Abstract
  • Google Scholar

• 186.

  AokiSTeradaHKosudaSShitaraNFujiiHSuzukiKet al. Supraophthalmic chemotherapy with long tapered catheter: distribution evaluated with intraarterial and intravenous Tc-99m HMPAO. Radiology. (1993) 188:347–50. 10.1148/radiology.188.2.8327676

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187.

  ChrousosGAOldfieldEHDoppmanJLCoganDG. Prevention of ocular toxicity of carmustine (BCNU) with supraophthalmic intracarotid infusion. Ophthalmology. (1986) 93:1471–5. 10.1016/S0161-6420(86)33544-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188.

  KappJPParkerJLTuckerEM. Supraophthalmic carotid infusion for brain chemotherapy. Experience with a new single-lumen catheter and maneuverable tip. J Neurosurg. (1985) 62:823–5. 10.3171/jns.1985.62.6.0823

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189.

  KappJPVanceRB. Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU. J Neuro Oncol. (1985) 3:5–11. 10.1007/BF00165165

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190.

  TamakiMOhnoKNiimiYAoyagiMNagashimaGIchimuraKet al. Parenchymal damage in the territory of the anterior choroidal artery following supraophthalmic intracarotid administration of CDDP for treatment of malignant gliomas. J Neuro Oncol. (1997) 35:65–72. 10.1023/A:1005847115488

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191.

  VanceRBKappJP. Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma. J Neuro Oncol. (1986) 3:287–90. 10.1007/BF00165576

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192.

  DebrunGMDavisKRHochbergFH. Superselective injection of BCNU through a latex calibrated-leak balloon. AJNR Am J Neuroradiol. (1983) 4:399–400.

  • Pubmed Abstract
  • Google Scholar

• 193.

  LarnerJMKershCRConstableWCKlinePFergusonRShortRet al. Phase I/II trial of superselective arterial 5-FU infusion with concomitant external beam radiation for patients with either anaplastic astrocytoma or glioblastoma multiforme. Am J Clin Oncol. (1991) 14:514–8. 10.1097/00000421-199112000-00010

  • CrossRef
  • Google Scholar

• 194.

  JeonJYKovanlikayaIBoockvarJAMaoXShinBBurkhardtJKet al. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study. AJNR Am J Neuroradiol. (2012) 33:2095–102. 10.3174/ajnr.A3091

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195.

  RiinaHABurkhardtJKSantillanABassaniLPatsalidesABoockvarJA. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of bevacizumab for the treatment of vestibular schwannomas in neurofibromatosis type 2. Interv Neuroradiol. (2012) 18:127–32. 10.1177/159101991201800201

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196.

  SuzukiSKurataATakagiHNakaharaKOkaHMiyasakaYet al. Superselective arterial chemotherapy for inoperable metastases in the dura mater and cranium. Interv Neuroradiol. (2002) 8:121–5. 10.1177/159101990200800203

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197.

  RongJChunhuaMYuanLNingMJinduoLBinWet al. Clinical interrogation and application of super-selective intracranial artery infusion chemotherapy for lung cancer patients with brain metastases. Indian J Cancer. (2015) 52(Suppl. 1):e22–5. 10.4103/0019-509X.168951

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198.

  BernhardtDAdebergSBozorgmehrFOpfermannNHoerner-RieberJKonigLet al. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J Neuro Oncol. (2017) 134:205–12. 10.1007/s11060-017-2510-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199.

  KepkaLCieslakEBujkoKFijuthJWierzchowskiM. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol. (2005) 44:389–98. 10.1080/02841860510029699

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200.

  GinosJZCooperAJDhawanVLaiJCStrotherSCAlcockNet al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med. (1987) 28:1844–52.

  • Pubmed Abstract
  • Google Scholar

• 201.

  Di ChiroGOldfieldEWrightDCDe MicheleDKatzDAPatronasNJet al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. (1988) 150:189–97. 10.2214/ajr.150.1.189

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202.

  LangenKJRoosenNKuwertTHerzogHKiwitJCRota KopsEet al. Early effects of intra-arterial chemotherapy in patients with brain tumours studied with PET: preliminary results. Nucl Med Commun. (1989) 10:779–90. 10.1097/00006231-198911000-00002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203.

  SasajimaTMineuraKSasakiJKowadaMTomuraNHatazawaJet al. Positron emission tomographic assessment of cerebral hemocirculation and glucose metabolism in malignant glioma following treatment with intracarotid recombinant human tumor necrosis factor-alpha. J Neuro Oncol. (1995) 23:67–73. 10.1007/BF01058461

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204.

  TomuraNHiranoHWatanabeOKatoKSasakiKWataraiJet al. Preliminary results with technetium-99m MIBI SPECT imaging in patients with brain tumors: correlation with histological and neuroradiological diagnoses and therapeutic response. Comput Med Imaging Graph. (1997) 21:293–8. 10.1016/S0895-6111(97)00026-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205.

  NambaHKobayashiSIwadateYSaegusaTSatoAWatanabeYet al. Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl-propyleneamine oxime–technical note. Neurol Medico Chirurgica. (1994) 34:832–5. 10.2176/nmc.34.832

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206.

  ShaniJBertramJRussellCDahalanRChenDCPartiRet al. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res. (1989) 49:1877–81.

  • Pubmed Abstract
  • Google Scholar

• 207.

  TomuraNHashimotoMSashiRHiranoHKobayashiMHiranoYet al. Superselective angio-CT of brain tumors. AJNR Am J Neuroradiol. (1996) 17:1073–80.

  • Pubmed Abstract
  • Google Scholar

• 208.

  HiraiTKorogiYOnoKYamashitaY. Evaluation of vascular supply with angio-computed tomography during intra-arterial chemotherapy for brain tumors. Cardiovasc Interv Radiol. (2005) 28:354–7. 10.1007/s00270-003-0094-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209.

  ArnoldDLShoubridgeEAEmrichJFeindelWVillemureJG. Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. Invest Radiol. (1989) 24:958–61. 10.1097/00004424-198912000-00007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210.

  ArnoldDLShoubridgeEAFeindelWVillemureJG. Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy. Can J Neurol Sci. (1987) 14:570–5.

  • Pubmed Abstract
  • Google Scholar

• 211.

  YoshikawaTAokiSHoriMNambuAKumagaiHArakiT. Time-resolved two-dimensional thick-slice magnetic resonance digital subtraction angiography in assessing brain tumors. Eur Radiol. (2000) 10:736–44. 10.1007/s003300050996

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212.

  ZawadzkiMWaleckiJKostkiewiczBKostyraKPearlMSSolaiyappanMet al. Republished: real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note. J Neurointerv Surg. (2019) 11:e3. 10.1136/neurintsurg-2018-014469.rep

  • CrossRef
  • Google Scholar

• 213.

  ChenSJiXLiuMXiaZZhengHYinQet al. The value of MRI in evaluating the efficacy and complications with the treatment of intra-arterial chemotherapy for retinoblastoma. Oncotarget. (2017) 8:38413–25. 10.18632/oncotarget.16423

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214.

  KimBKimKImKHKimJHLeeJHJeonPet al. Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor. J Neuro Oncol. (2016) 127:243–51. 10.1007/s11060-015-2041-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215.

  CaoMMaoJDuanXLuLZhangFLinBet al. In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging. Int J Cancer. (2018) 142:1033–46. 10.1002/ijc.31113

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216.

  QiaoYGuminJMacLellanCJGaoFBouchardRLangFFet al. Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection. Nanotechnology. (2018) 29:165101. 10.1088/1361-6528/aaaf16

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217.

  TeradaTNambuKHyotaniGMiyamotoKTsuuraMNakamuraYet al. A method for quantitative measurement of cerebral vascular permeability using X-ray CT and iodinated contrast medium. Neuroradiology. (1992) 34:290–6. 10.1007/BF00588184

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218.

  BoxermanJLShiroishiMSEllingsonBMPopeWB. Dynamic susceptibility contrast MR imaging in glioma: review of current clinical practice. Magnetic Resonance Imaging Clin North Am. (2016) 24:649–70. 10.1016/j.mric.2016.06.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219.

  ThomsenHSMorcosSKAlménTBellinMFBertolottoMBongartzGet al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. (2013) 23:307–18. 10.1007/s00330-012-2597-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220.

  XuQLiuQGeHGeXWuJQuJet al. Tumor recurrence versus treatment effects in glioma A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging. Medicine. (2017) 96:e9332. 10.1097/MD.0000000000009332

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 221.

  ZhouLWangYPinhoMCPanEXiYMaldjianJAet al. Intrasession reliability of arterial spin-labeled MRI-measured noncontrast perfusion in glioblastoma at 3 T. Tomography. (2020) 6:139–47. 10.18383/j.tom.2020.00010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222.

  TurskiPKalinkeTStrotherLPermanWScottGKornguthS. Magnetic resonance imaging of rabbit brain after intracarotid injection of large multivesicular liposomes containing paramagnetic metals and DTPA. Magnetic Resonance Med. (1988) 7:184–96. 10.1002/mrm.1910070206

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223.

  ChertokBMoffatBADavidAEYuFBergemannCRossBDet al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. (2008) 29:487–96. 10.1016/j.biomaterials.2007.08.050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 224.

  MehtaRV. Synthesis of magnetic nanoparticles and their dispersions with special reference to applications in biomedicine and biotechnology. Mater Sci Eng C Mater Biol Appl. (2017) 79:901–16. 10.1016/j.msec.2017.05.135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 225.

  LübbeASBergemannCHuhntWFrickeTRiessHBrockJWet al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. (1996) 56:4694–701.

  • Pubmed Abstract
  • Google Scholar

• 226.

  LundbergJJussingELiuZMengQRaoMSamenEet al. Safety of intra-arterial injection with tumor-activated T cells to the rabbit brain evaluated by MRI and SPECT/CT. Cell Transplant. (2017) 26:283–92. 10.3727/096368916X693347

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 227.

  CohenARPietronigroDDCraviotoHFlammES. Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU. J Neurosurg. (1986) 65:671–8. 10.3171/jns.1986.65.5.0671

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 228.

  ResioMJDeVroomHL. Spiromustine and intracarotid artery cisplatin in the treatment of glioblastoma multiforme. J Neurosci Nurs. (1986) 18:13–22. 10.1097/01376517-198602000-00006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 229.

  StewartDJDahrougeSWeeMAitkenSHugenholtzH. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neuro Oncol. (1995) 24:189–94. 10.1007/BF01078489

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 230.

  WatneKHannisdalENomeOHagerBWesterKHeierMet al. Combined intra-arterial chemotherapy followed by radiation in astrocytomas. J Neuro Oncol. (1992) 14:73–80. 10.1007/BF00170947

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 231.

  SchemBCKrossnesBK. Enhancement of ACNU treatment of the BT4An rat glioma by local brain hyperthermia and intra-arterial drug administration. Eur J Cancer. (1995) 31A:1869–74. 10.1016/0959-8049(95)00381-R

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 232.

  MoritaKTanakaRKakinumaKTakahashiHMotoyamaH. Combination therapy of rat brain tumours using localized interstitial hyperthermia and intra-arterial chemotherapy. Int J Hyperthermia. (2003) 19:204–12. 10.1080/02656730210147295

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 233.

  UzukaTTakahashiHTanakaR. Interstitial hyperthermia with intra-arterial injection of adriamycin for malignant glioma. Neurol Medico Chirurgica. (2006) 46:19–23. discussion: 23. 10.2176/nmc.46.19

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 234.

  RodriguezAZugbiSRequejoFDeuASamporCSgroiMet al. Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. Pediatric Blood Cancer. (2018) 65:e27385. 10.1002/pbc.27385

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 235.

  GreenbergHSChandlerWFDiazRFEnsmingerWDJunckLPageMAet al. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas. J Neurosurg. (1988) 69:500–5. 10.3171/jns.1988.69.4.0500

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 236.

  LiuSKJakowatzJGPollackRBCeraldiCYamamotoRDettCet al. Effects of intracarotid and intravenous infusion of human TNF and LT on established intracerebral rat gliomas. Lymphokine Cytokine Res. (1991) 10:189–94.

  • Pubmed Abstract
  • Google Scholar

• 237.

  YoshidaJWakabayashiTMizunoMSugitaKYoshidaTHoriSet al. Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J Neurosurg. (1992) 77:78–83. 10.3171/jns.1992.77.1.0078

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 238.

  DebinskiWObiriNIPowersSKPastanIPuriRK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res. (1995) 1:1253–8.

  • Pubmed Abstract
  • Google Scholar

• 239.

  SampsonJHAkabaniGArcherGEBergerMSColemanREFriedmanAHet al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. (2008) 10:320–9. 10.1215/15228517-2008-012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 240.

  AbeTWakimotoHBooksteinRManevalDCChioccaEABasilionJP. Intra-arterial delivery of p53-containingadenoviral vector into experimental brain tumors. Cancer Gene Ther. (2002) 9:228–35. 10.1038/sj.cgt.7700437

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 241.

  KogaHInamuraTIkezakiKSamotoKMatsukadoKFukuiM. Selective transvascular delivery of oligodeoxynucleotides to experimental brain tumors. J Neuro Oncol. (1999) 43:143–51. 10.1023/A:1006210901856

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 242.

  BarnettFHScharer-SchukszMWoodMYuXWagnerTEFriedlanderM. Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther. (2004) 11:1283–9. 10.1038/sj.gt.3302287

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 243.

  LiuRMartuzaRLRabkinSD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. (2005) 12:647–54. 10.1038/sj.gt.3302445

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 244.

  FoleyCPRubinDGSantillanASondhiDDykeJPGobinYPet al. Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. J Control Release. (2014) 196:71–8. 10.1016/j.jconrel.2014.09.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 245.

  JiNWengDLiuCGuZChenSGuoYet al. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget. (2016) 7:4369–78. 10.18632/oncotarget.6737

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 246.

  ChioccaEAAbbedKMTatterSLouisDNHochbergFHBarkerFet al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. (2004) 10:958–66. 10.1016/j.ymthe.2004.07.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 247.

  PapanastassiouVRamplingRFraserMPettyRHadleyDNicollJet al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. (2002) 9:398–406. 10.1038/sj.gt.3301664

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 248.

  GeoergerBTangCBCesanoAVisonneauSMarwahaSJudyKDet al. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro Oncol. (2000) 2:103–13. 10.1093/neuonc/2.2.103

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 249.

  WeilemannFSteinmetzAKirschMButtlerAKunzeSKuhlischEet al. Prevention of brain metastasis formation by local expression of interleukin-4 or hemagglutinin antigen. Zentralblatt Neurochirurgie. (2003) 64:65–70. 10.1055/s-2003-40374

  • CrossRef
  • Google Scholar

• 250.

  YongRLShinojimaNFueyoJGuminJVecilGGMariniFCet al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. (2009) 69:8932–40. 10.1158/0008-5472.CAN-08-3873

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 251.

  HerrmannAMMeckelSGounisMJKringeLMotschallEMullingCet al. Large animals in neurointerventional research: a systematic review on models, techniques and their application in endovascular procedures for stroke, aneurysms and vascular malformations. J Cereb Blood Flow Metab. (2019) 39:375–94. 10.1177/0271678X19827446

  • Pubmed Abstract
  • CrossRef
  • Google Scholar